Cargando…
Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial
BACKGROUND: Skin rash is the most common adverse effect associated with epidermal growth factor receptor inhibitors (EGFRIs). The study has observed the efficacy and safety of Zhiyang Pingfu Liquid in the treatment of EGFRIs-related moderate and severe rash. METHODS: Patients suffering from EGFRIs-r...
Autores principales: | Zhang, Jingyi, Lu, Xingyu, Zhang, Xu, Tan, Kexin, Li, Jia, Cui, Huijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703570/ https://www.ncbi.nlm.nih.gov/pubmed/36419383 http://dx.doi.org/10.1177/15347354221140409 |
Ejemplares similares
-
Xerosis and pruritus as major EGFRI-associated adverse events
por: Clabbers, Julia M. K., et al.
Publicado: (2015) -
A Meta-Analysis of Randomized Clinical Trials of Runzao Zhiyang Capsule in Chronic Urticaria
por: Ye, Shengzhen, et al.
Publicado: (2022) -
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
por: Wong, Siu-Fun, et al.
Publicado: (2020) -
Efficacy and safety of Runzao Zhiyang capsule for chronic urticaria: a systematic review and meta-analysis of randomized controlled trials
por: Zhang, Jian-Feng, et al.
Publicado: (2023) -
Efficacy and Safety of Runzao Zhiyang Capsule as an Add-On Therapy for Chronic Eczema: A Systematic Review and Meta-Analysis
por: Li, Ming, et al.
Publicado: (2021)